Animal Research Context: Scaling from Rodents Preclinical studies with Dihexa and angiotensin IV analogues employed doses that ranged considerably depending on species, route, and outcome measured: Intravenous (IV) Administration Animal studies using intravenous dosing (which bypasses absorption barriers and achieves near-complete bioavailability) reported cognitive and neuroprotective effects at: 0.1 to 2.0 mg/kg in rodent studies (McCoy et al., 2013) Doses at the higher end of this range (12 mg/kg IV) produced robust behavioral effects For a 70 kg human, equivalent to 70140 mg total IV dose (crude extrapolation) However, direct extrapolation from rodents to humans is unreliable due to differences in metabolism, brain penetration, and receptor sensitivity Intraperitoneal (IP) Administration IP dosing (injection into the abdominal cavity, with slower absorption than IV) showed effects at: Up to 10 mg/kg in some studies Lower bioavailability than IV, requiring higher nominal doses for similar effects This route is not practical for human use Why Rodent Dosing Doesn't Directly Translate Rodent pharmacokinetics differ substantially from humans

Unlike many other compounds, BPC 157 does not just offer temporary relief but contributes to the long-term health of the stomach lining and other tissues
Supports Pets with GI Disease: Delivers reliable systemic B12 in dogs and cats with inflammatory bowel disease or exocrine pancreatic insufficiency where oral absorption is compromised
Third-party Certificate of Analysis (CoA)
At The Wellness Lounge, were excited to announce that we now offer personalized BPC-157 kits , tailored to your unique needs and paired with in-house therapies like contrast therapy, glutathione IV push, and PRP joint injections for amplified results